A single dose of dolutegravir is not the subject of this article. The ODYSSEY trial (phase I/II) showed that twice-daily dolutegravir is safe and adequate for children with HIV-associated tuberculosis (TB) receiving rifampicin[1][2][3]. A substudy followed 20 children aged 4 weeks to less than 18 years, measuring blood levels of dolutegravir to confirm efficacy against HIV[2]. Rifampicin (geometric mean Cmax 5.1 mg/L) affects dolutegravir levels, but a double daily dose based on weight compensates[1][3]. During a median follow-up of 31 weeks (IQR 30–40), 37 children had 15 serious adverse events (grade 3+ in 30%), including 10 serious and 2 deaths, but none related to dolutegravir[3]. No adverse events were considered related to dolutegravir[1][3]. After stopping rifampicin, children return to a single dose[2]. This is the first study on the interaction of rifampicin and dolutegravir in children with HIV-TB[2][3].